PTPN11 and juvenile myelomonocytic leukemia: PTPN11 is the most common target of genetic mutations in JMML (71,72), and 35% of patients with JMML have activating mutations in tyrosine phosphatase PTPN11 (SHP2), a known positive regulation of the RAS pathway.